Form 4: BioCryst Pharmaceuticals Director Acquires Shares in Lieu of Cash Retainer
SEC Form 4 Filing
Director Vincent Milano acquired 999 shares of BioCryst Pharmaceuticals common stock in lieu of a portion of his quarterly cash retainer.
Summary
- On February 29, 2024, Vincent Milano, a director of BioCryst Pharmaceuticals Inc., acquired 999 shares of common stock.
- The acquisition was made in lieu of 50% of his quarterly cash Board Member retainer of $11,250.
- The price per share was $5.63.
- Following the transaction, Milano directly owns 51,997 shares of BioCryst Pharmaceuticals Inc.
Sentiment
Score: 6
Explanation: Neutral sentiment as it reflects a standard compensation practice. The director taking shares instead of cash could be seen as a slightly positive signal.
Positives
- Director's decision to take shares instead of cash may signal confidence in the company's future.
Industry Context
Directors often receive equity as part of their compensation, aligning their interests with those of shareholders. This is a common practice in the pharmaceutical industry.
Related Party Transactions
- The transaction involves a director receiving shares as part of their compensation, which is a related party transaction.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a small number of shares being issued to a director.
Key Dates
| Date | Description |
|---|---|
| 02/29/2024 | Date of transaction: Vincent Milano acquired 999 shares of common stock. |
| 03/04/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.